CELGENE-GC-LTFU-001
Phase II/III
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Gene-Modified T Cells
EMN30-64007957MMY3003-MAJESTEC
Phase III
OPEN TO ACCRUAL
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)
IIT-AKHTAR-CILTA-TALQ
Phase I
OPEN TO ACCRUAL
A Phase Ib Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients with Relapsed/Refractory Multiple Myeloma
JNJ-MY4002-CARTINUE-LTFU
Phase IV
OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
MODERNA-MRNA-2808-P101
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, Open-Label, Multicenter Study of mRNA-2808 in Participants with Relapsed or Refractory Multiple Myeloma
SWOG-S2213
Phase III
OPEN TO ACCRUAL
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis